{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:20:31Z","timestamp":1773044431602,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004637","name":"Nanchang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.leukres.2024.107548","type":"journal-article","created":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T05:30:11Z","timestamp":1720330211000},"page":"107548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["PI3K\/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"144","author":[{"given":"Chunfang","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10129","key":"10.1016\/j.leukres.2024.107548_bib1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.leukres.2024.107548_bib2","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/bloodadvances.2017006809","article-title":"Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia","volume":"1","author":"Maharaj","year":"2017","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2024.107548_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-024-01001-1","article-title":"Update on the management of relapsed\/refractory chronic lymphocytic leukemia","volume":"14","author":"Bennett","year":"2024","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2024.107548_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/genes14122182","article-title":"Resisting the resistance: navigating BTK mutations in chronic lymphocytic leukemia (CLL)","volume":"14","author":"Chirino","year":"2023","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib6","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2024.107548_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2024.107548_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.leukres.2024.107548_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107548_bib11","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107548_bib12","article-title":"Mutations detected in real world clinical sequencing during BTK inhibitor treatment in CLL","author":"Brown","year":"2024","journal-title":"Res. Sq."},{"issue":"3","key":"10.1016\/j.leukres.2024.107548_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","article-title":"DeepCRISPR: optimized CRISPR guide RNA design by deep learning","volume":"19","author":"Chuai","year":"2018","journal-title":"Genome Biol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107548_bib15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14789450.2021.2020655","article-title":"Reverse phase protein arrays in acute leukemia: investigative and methodological challenges","volume":"18","author":"Hoff","year":"2021","journal-title":"Expert Rev. Proteom."},{"issue":"3","key":"10.1016\/j.leukres.2024.107548_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031589","article-title":"Treatment of double-refractory chronic lymphocytic leukemia-an unmet clinical need","volume":"25","author":"Zygmunciak","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2024.107548_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The relation between PI3K\/AKT signalling pathway and cancer","volume":"698","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.leukres.2024.107548_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2024.107548_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107548_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"issue":"23","key":"10.1016\/j.leukres.2024.107548_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312673","article-title":"BTK and PI3K inhibitors reveal synergistic inhibitory anti-tumoral effects in canine diffuse large B-cell lymphoma cells","volume":"22","author":"Kong","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2024.107548_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-021-00066-9","article-title":"Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma","volume":"3","author":"Vann","year":"2022","journal-title":"Mol. Biomed."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:43:24Z","timestamp":1736203404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":24,"alternative-id":["S0145212624001140"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107548","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K\/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107548"}}